Home Featured Page 279

Featured

Latest

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Karina Bashir on Psychedelics, Islam, and Human Rights

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Differentiating DMT and Near-Death Experiences

New Texas Legislation Will Allow State to Study MDMA, Psilocybin as...

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke...

PTSF47 – Covid, Ketamine, and Human Rights

Massachusetts General Hospital to Study How Psychedelics Influence the Brain

Can LSD cure our pandemic anxiety? MindMed is spending big to...

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters...

The Veterans’ Experience: Psychedelic Treatments for PTSD

Red Light Holland Receives Receipt for Final Short-form Prospectus for Previously...

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in...

1...278279280...293 Page 279 of 293

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State & Exploring Ibogaine’s Potential

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy, and Perception (Part 1)

Karina Bashir on Psychedelics, Islam, and Human Rights

Kristen Nash and Erica Siegel on Risk Reduction and Psychedelic Safety

Differentiating DMT and Near-Death Experiences

New Texas Legislation Will Allow State to Study MDMA, Psilocybin as...

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke...

PTSF47 – Covid, Ketamine, and Human Rights

Massachusetts General Hospital to Study How Psychedelics Influence the Brain

Can LSD cure our pandemic anxiety? MindMed is spending big to...

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters...

The Veterans’ Experience: Psychedelic Treatments for PTSD

Red Light Holland Receives Receipt for Final Short-form Prospectus for Previously...

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in...

EDITOR PICKS

June 2025 Psychedelic Patent Update

Alan Davis – Psychedelic Research and Patient Safety at Ohio State...

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference — Plasticity, Psychotherapy,...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY